» Articles » PMID: 19566788

Naturally Occurring Amino-acid Substitutions to Nucleos(t)ide Analogues in Treatment Naive Turkish Patients with Chronic Hepatitis B

Overview
Journal J Viral Hepat
Specialty Gastroenterology
Date 2009 Jul 2
PMID 19566788
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Naturally occurring amino-acid substitutions in the hepatitis B virus (HBV) polymerase gene may be responsible for resistance to nucleoside/nucleotide (NUCs) analogues. To date, only pre-existing lamivudine resistance has been extensively studied. The aim of the present study was to determine the naturally occurring or pre-existing amino-acid substitutions related to NUCs in treatment naive Turkish patients with chronic hepatitis B (CHB). The investigation involved a total of 88 patients (65 males and 23 females; mean age, 34 years; range, 15-61 years) who were diagnosed with CHB between April 2008 and January 2009. According to HBeAg status, 66 patients were HBeAg-negative and 22 patients were HBeAg positive. Naturally occurring substitutions in the HBV polymerase region were detected by DNA sequencing in 17 (19%) and 30 (34%) patients, based on manual and geno2pheno tool database interpretation, respectively. Each amino-acid substitution appeared alone and included rtA194T, rtV214A, rtQ215S, rtI233V and rtN236T. The median values for viral load, ALT and AST were 3.3 log(10) (2.0-6.0) IU/mL, 36 (12-515) U/L and 27 (13-284) U/L, respectively, but these did not correlate with the observed amino-acid substitutions in the polymerase region. By direct sequencing, genotype D of HBV was found to still be dominant among Turkish patients. In conclusion, every patient who is diagnosed with CHB should be monitored before the start of treatment for more effective management of patient treatment options.

Citing Articles

Molecular detection of hepatitis B virus genotype E with immune escape mutations in chronic hepatitis B patients on long-term antiviral therapy in Jos, Nigeria.

Anejo-Okopi J, Okeke E, Davwar P, Onwuamah C, Onywera H, Omaiye P Afr J Lab Med. 2022; 11(1):1677.

PMID: 36337771 PMC: 9634812. DOI: 10.4102/ajlm.v11i1.1677.


Prevalence of Potential Resistance Related Variants Among Chinese Chronic Hepatitis B Patients Not Receiving Nucleos(T)ide Analogues.

Qian F, Zou W, Jin F, Li D, Shen Y Infect Drug Resist. 2020; 13:2407-2416.

PMID: 32765014 PMC: 7381783. DOI: 10.2147/IDR.S249476.


An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors.

Mohebbi A, Lorestani N, Tahamtan A, Kargar N, Tabarraei A Front Microbiol. 2018; 9:662.

PMID: 29675010 PMC: 5895781. DOI: 10.3389/fmicb.2018.00662.


Molecular epidemiology of hepatitis B virus isolated from Bangladesh.

Shaha M, Hoque S, Rahman S Springerplus. 2016; 5(1):1513.

PMID: 27652086 PMC: 5016485. DOI: 10.1186/s40064-016-3174-5.


Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy.

Moehlen M, de Medina M, Hill M, Jeffers L, Schiff E, Martin P ISRN Hepatol. 2016; 2013:130384.

PMID: 27335823 PMC: 4890864. DOI: 10.1155/2013/130384.